FY2028 Earnings Estimate for TPST Issued By William Blair

Tempest Therapeutics, Inc. (NASDAQ:TPST) – William Blair issued their FY2028 earnings per share (EPS) estimates for Tempest Therapeutics in a research report issued on Thursday, March 27th. William Blair analyst M. Phipps anticipates that the company will post earnings of ($1.60) per share for the year. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The company had revenue of $0.49 million during the quarter.

TPST has been the topic of a number of other reports. HC Wainwright decreased their price target on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Scotiabank lowered their price objective on shares of Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a research note on Friday.

Tempest Therapeutics Trading Down 8.1 %

NASDAQ TPST opened at $0.77 on Monday. The firm has a market cap of $33.70 million, a PE ratio of -0.50 and a beta of -1.83. Tempest Therapeutics has a 1-year low of $0.70 and a 1-year high of $6.00. The stock has a 50-day moving average of $0.87 and a 200-day moving average of $0.97.

Institutional Trading of Tempest Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TPST. Versant Venture Management LLC purchased a new position in Tempest Therapeutics during the 4th quarter valued at $2,927,000. Jane Street Group LLC purchased a new position in shares of Tempest Therapeutics during the fourth quarter valued at about $411,000. Millennium Management LLC purchased a new position in shares of Tempest Therapeutics during the fourth quarter valued at about $158,000. XTX Topco Ltd raised its stake in Tempest Therapeutics by 570.3% in the fourth quarter. XTX Topco Ltd now owns 160,807 shares of the company’s stock worth $134,000 after buying an additional 136,818 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Tempest Therapeutics by 61.0% in the fourth quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock worth $296,000 after buying an additional 134,209 shares during the period. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.